Berlin/Breda, 13 October 2026. Eckert & Ziegler Brazil, a regional subsidiary of the global nuclear medicine group Eckert & Ziegler SE (ISIN DE0005659700, TecDAX), and TerThera announced today the signing of a strategic supply agreement for the precursor Terbium-161.

Under the terms of the agreement, TerThera will supply its GMP-compliant non-carrier-added (n.c.a.) Terbium-161 (Tb-161) to Eckert & Ziegler Brazil. This partnership establishes a critical and reliable supply chain for the innovative isotope in South America, directly providing Brazilian patients access to the next generation of radioligand therapies. Moreover, the availability of GMP-grade Tb-161 will allow local pharmaceutical developers and clinical institutions to investigate the combination of Tb-161 with novel peptides, antibodies, and FAP-inhibitors to target a broad spectrum of oncological indications. The agreement, between Eckert & Ziegler Brazil and TerThera, will bring the next generation of Radioligand Therapy (RLT)  to Brazil and allow access to a novel radiopharmaceutical for cancer healthcare.

Terbium-161, a carrier free lanthanide produced by neutron activation, is a highly promising radionuclide for Radioligand Therapy (RLT) exhibiting comparable chemical characteristics to known radiolanthanides that has the potential, due to highest addition of Auger electronic emission with a higher linear energy transfer, to improve anti-tumor capabilities for primary and (micro)metastasized cancers. The latest clinical results has shown a promising and effective anti-tumor response, even after treatment stops of conventional medicine, providing for a new therapy option by depositing a highest but localized tumor dose with limited impact on healthy tissue.

Expanding Local Theranostic Infrastructure
“It is a great milestone that after six years of absence we are back in Brazil with a potentially better radionuclide,” said Philippe van Overeem, CEO of TerThera. “Having supplied Lu-177 to Brazil for almost two decades, I know firsthand the passion and capability of the local nuclear medicine community. Returning to this market with GMP-grade Terbium-161 allows us to build on that legacy and give Brazilian doctors and researchers a powerful, next-generation tool to treat micro-metastases and complex tumors more effectively.”

The agreement leverages Eckert & Ziegler’s robust presence in Latin America, combining TerThera’s unique isotope production capabilities with a powerful regional distribution and manufacturing network.

“We are proud to partner with TerThera to bring this highly promising isotope to South America,” stated Fabrício Diel, the Managing Director of Eckert & Ziegler Brazil. “Integrating Terbium-161 into our portfolio perfectly aligns with our mission of Contributing to Saving Lives and our goal to expand local access to strategic theranostic solutions. By combining this premium radionuclide with advanced targeting agents here in Brazil, we are shortening the supply chain and opening new clinical horizons for oncology patients across the region.”

About TerThera BV
TerThera is a radionuclide production focused company based in The Netherlands. The founders and the staff of TerThera have decades of experience in the nuclear medicine industry and are giving their full focus on the production of the innovative radionuclide Terbium-161 (Tb-161). TerThera is building a global platform to meet the growing demand for radionuclides in oncology and nuclear medicine. www.terthera.com

About Eckert & Ziegler
Eckert & Ziegler SE, with more than 1,100 employees, is THE leading independent radioisotope supplier and a specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
www.ezag.com

Your contact:
Eckert & Ziegler SE, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com

A landmark study published in Frontiers in Medicine by Albano, Paone, and Treglia delivers critical clinical validation for hospitals looking to adopt next-generation radioligand therapy. As the first-ever systematic review and meta-analysis of its kind, the study analyzed data from 80 metastatic castration-resistant prostate cancer (mCRPC) patients across 291 cycles. It conclusively proves that Terbium-161 (Tb-161) is not only highly effective but also exceptionally safe.

The clinical outcomes provide a compelling case for nuclear medicine departments. The pooled analysis demonstrated a remarkable 83.9% disease control rate and a 50.2% objective PSA response rate. Crucially, this high efficacy was maintained in late-stage patients who had previously failed conventional Lutetium-177 or Actinium-225 therapies, proving that Tb-161 can overcome established resistance pathways. Despite this powerful therapeutic effect, severe side effects were rare, confirming that the treatment fits safely and seamlessly into existing outpatient and inpatient hospital workflows.

This clinical advantage is driven by the unique physics of Terbium-161. By co-emitting medium-range beta particles and short-range Auger and conversion electrons, it delivers a massive, highly localized energy dose. This dual action successfully eradicates single cancer cells and micrometastases that traditional beta-only emitters often miss. Since Terbium-161 shares identical chelator chemistry with Lutetium-177, your hospital can easily adopt these protocols using your existing radiopharmacy infrastructure. Partner with TerThera today to secure a reliable, commercial-scale supply of high-purity Terbium-161 for your clinic.